Skip to main content

Anti-hypertensive drugs

10-13-2022 | Anti-hypertensive medications | News

TIME of antihypertensive administration ‘should be shared decision’

The TIME study finds no difference between morning and evening administration of antihypertensive medications in terms of preventing major adverse cardiovascular events.

Doctor measuring arterial blood pressure on arm of a patient

07-28-2022 | Anti-hypertensive medications | News

No justification for bespoke antihypertensive intervention in type 2 diabetes

The absolute benefit of blood pressure reduction on cardiovascular risk does not differ according to whether or not people have type 2 diabetes, shows an individual participant data meta-analysis.

White electric tonometer indicating blood pressure and pills on black background

03-03-2022 | Anti-hypertensive medications | News

Verapamil type 1 diabetes benefits sustained for at least 2 years

Researchers report that the antihypertensive medication verapamil preserves beta-cell function and reduces insulin needs in adults with type 1 diabetes during up to 2 years of treatment.

Person having blood pressure checked

11-17-2021 | Diabetes prevention | News

Lowering blood pressure may help type 2 diabetes prevention

Reducing blood pressure may be an effective strategy for the prevention of new-onset type 2 diabetes, suggest researchers from the Blood Pressure Lowering Treatment Trialists’ Collaboration.

Glucose monitor, heart, and stethoscope

09-26-2020 | EASD 2020 | Conference coverage | News

Cardioprotective measures neglected in young-onset type 2 diabetes

People with type 2 diabetes, especially young people, do not receive treatment for hypertension and dyslipidemia in a timely manner, even when they have high cardiovascular risk, study results show.

10-24-2019 | Hypertension | News

Bedtime hypertension medication best for averting CV events

A large randomized trial may have settled the question of whether it is best to take blood pressure medications in the morning or evening.

Kidneys

09-20-2019 | Nephropathy | EASD 2019 | News

Mixed results for PRIORITY diabetic nephropathy trial

The CKD273 proteomic biomarker panel can predict which people with type 2 diabetes will develop detectable diabetic nephropathy, but early intervention with spironolactone does not mitigate this risk, report the PRIORITY investigators.

12-05-2018 | Empagliflozin | News

Empagliflozin beneficial for uncontrolled nocturnal hypertension

The addition of empagliflozin reduces nighttime blood pressure in older diabetes patients who have nocturnal hypertension despite medication including angiotensin receptor blockers, show findings from a randomized trial.